Features that predict responsiveness to chemotherapy and endocrine therapies

M. Bonetti, R. D. Gelber, A. Goldhirsch, M. Castiglione-Gertsch, A. S. Coates

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Prognostic factors, characterizing the background level of risk of relapse, and predictive factors, characterizing the degree of responsiveness to a specific treatment, are both used to select adjuvant therapies for patients with early-stage breast cancer. Determining how best to utilize available factors is challenging. We review various prognostic and predictive factors and present examples to illustrate how these factors can be used to improve our understanding about selection of adjuvant treatments, re-evaluation of data from previous clinical trials and design of future studies. Steroid-hormone-receptor status of the primary tumour and patient age/menopausal status (primarily reflecting the robustness of ovarian function) are the key features that predict responsiveness to chemotherapy and endocrine therapies. Qualitative interactions between these factors, and effects of combining chemotherapy and endocrine therapies, may confound treatment comparison. The STEPP (Subpopulation Treatment Effect Pattern Plots) method, by investigating the patterns of treatment effects within randomized clinical trials or datasets from meta-analyses, will help to identify features that predict responsiveness to the treatments under study without the pitfalls of selective retrospective subset analysis. Subset analyses according to steroid-hormone-receptor status and patient age should now be considered as prospectively defined. Future clinical trials should be designed as tailored treatment investigations, with endocrine therapies being evaluated within populations of patients with endocrine-responsive tumours, and chemotherapy questions being addressed within populations of patients with endocrine non-responsive disease.

Original languageEnglish
Pages (from-to)147-157
Number of pages11
JournalBreast
Volume10
Issue numberSUPPL. 3
Publication statusPublished - 2001

Fingerprint

Drug Therapy
Therapeutics
Steroid Receptors
Clinical Trials
Hormones
Population
Meta-Analysis
Neoplasms
Randomized Controlled Trials
Breast Neoplasms
Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Bonetti, M., Gelber, R. D., Goldhirsch, A., Castiglione-Gertsch, M., & Coates, A. S. (2001). Features that predict responsiveness to chemotherapy and endocrine therapies. Breast, 10(SUPPL. 3), 147-157.

Features that predict responsiveness to chemotherapy and endocrine therapies. / Bonetti, M.; Gelber, R. D.; Goldhirsch, A.; Castiglione-Gertsch, M.; Coates, A. S.

In: Breast, Vol. 10, No. SUPPL. 3, 2001, p. 147-157.

Research output: Contribution to journalArticle

Bonetti, M, Gelber, RD, Goldhirsch, A, Castiglione-Gertsch, M & Coates, AS 2001, 'Features that predict responsiveness to chemotherapy and endocrine therapies', Breast, vol. 10, no. SUPPL. 3, pp. 147-157.
Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Coates AS. Features that predict responsiveness to chemotherapy and endocrine therapies. Breast. 2001;10(SUPPL. 3):147-157.
Bonetti, M. ; Gelber, R. D. ; Goldhirsch, A. ; Castiglione-Gertsch, M. ; Coates, A. S. / Features that predict responsiveness to chemotherapy and endocrine therapies. In: Breast. 2001 ; Vol. 10, No. SUPPL. 3. pp. 147-157.
@article{6c6a024db6d542e29b12d939347740f9,
title = "Features that predict responsiveness to chemotherapy and endocrine therapies",
abstract = "Prognostic factors, characterizing the background level of risk of relapse, and predictive factors, characterizing the degree of responsiveness to a specific treatment, are both used to select adjuvant therapies for patients with early-stage breast cancer. Determining how best to utilize available factors is challenging. We review various prognostic and predictive factors and present examples to illustrate how these factors can be used to improve our understanding about selection of adjuvant treatments, re-evaluation of data from previous clinical trials and design of future studies. Steroid-hormone-receptor status of the primary tumour and patient age/menopausal status (primarily reflecting the robustness of ovarian function) are the key features that predict responsiveness to chemotherapy and endocrine therapies. Qualitative interactions between these factors, and effects of combining chemotherapy and endocrine therapies, may confound treatment comparison. The STEPP (Subpopulation Treatment Effect Pattern Plots) method, by investigating the patterns of treatment effects within randomized clinical trials or datasets from meta-analyses, will help to identify features that predict responsiveness to the treatments under study without the pitfalls of selective retrospective subset analysis. Subset analyses according to steroid-hormone-receptor status and patient age should now be considered as prospectively defined. Future clinical trials should be designed as tailored treatment investigations, with endocrine therapies being evaluated within populations of patients with endocrine-responsive tumours, and chemotherapy questions being addressed within populations of patients with endocrine non-responsive disease.",
author = "M. Bonetti and Gelber, {R. D.} and A. Goldhirsch and M. Castiglione-Gertsch and Coates, {A. S.}",
year = "2001",
language = "English",
volume = "10",
pages = "147--157",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Features that predict responsiveness to chemotherapy and endocrine therapies

AU - Bonetti, M.

AU - Gelber, R. D.

AU - Goldhirsch, A.

AU - Castiglione-Gertsch, M.

AU - Coates, A. S.

PY - 2001

Y1 - 2001

N2 - Prognostic factors, characterizing the background level of risk of relapse, and predictive factors, characterizing the degree of responsiveness to a specific treatment, are both used to select adjuvant therapies for patients with early-stage breast cancer. Determining how best to utilize available factors is challenging. We review various prognostic and predictive factors and present examples to illustrate how these factors can be used to improve our understanding about selection of adjuvant treatments, re-evaluation of data from previous clinical trials and design of future studies. Steroid-hormone-receptor status of the primary tumour and patient age/menopausal status (primarily reflecting the robustness of ovarian function) are the key features that predict responsiveness to chemotherapy and endocrine therapies. Qualitative interactions between these factors, and effects of combining chemotherapy and endocrine therapies, may confound treatment comparison. The STEPP (Subpopulation Treatment Effect Pattern Plots) method, by investigating the patterns of treatment effects within randomized clinical trials or datasets from meta-analyses, will help to identify features that predict responsiveness to the treatments under study without the pitfalls of selective retrospective subset analysis. Subset analyses according to steroid-hormone-receptor status and patient age should now be considered as prospectively defined. Future clinical trials should be designed as tailored treatment investigations, with endocrine therapies being evaluated within populations of patients with endocrine-responsive tumours, and chemotherapy questions being addressed within populations of patients with endocrine non-responsive disease.

AB - Prognostic factors, characterizing the background level of risk of relapse, and predictive factors, characterizing the degree of responsiveness to a specific treatment, are both used to select adjuvant therapies for patients with early-stage breast cancer. Determining how best to utilize available factors is challenging. We review various prognostic and predictive factors and present examples to illustrate how these factors can be used to improve our understanding about selection of adjuvant treatments, re-evaluation of data from previous clinical trials and design of future studies. Steroid-hormone-receptor status of the primary tumour and patient age/menopausal status (primarily reflecting the robustness of ovarian function) are the key features that predict responsiveness to chemotherapy and endocrine therapies. Qualitative interactions between these factors, and effects of combining chemotherapy and endocrine therapies, may confound treatment comparison. The STEPP (Subpopulation Treatment Effect Pattern Plots) method, by investigating the patterns of treatment effects within randomized clinical trials or datasets from meta-analyses, will help to identify features that predict responsiveness to the treatments under study without the pitfalls of selective retrospective subset analysis. Subset analyses according to steroid-hormone-receptor status and patient age should now be considered as prospectively defined. Future clinical trials should be designed as tailored treatment investigations, with endocrine therapies being evaluated within populations of patients with endocrine-responsive tumours, and chemotherapy questions being addressed within populations of patients with endocrine non-responsive disease.

UR - http://www.scopus.com/inward/record.url?scp=0034916052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034916052&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034916052

VL - 10

SP - 147

EP - 157

JO - Breast

JF - Breast

SN - 0960-9776

IS - SUPPL. 3

ER -